view more. Clin Transl Oncol. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. We also use them to share usage information with our partners. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA Polly Firs Before We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . The cytosolic DNA-sensing cGAS-STING pathway in cancer. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. Bethesda, MD 20894, Web Policies If this sounds like you, please get in touch with us. 700, Boston, MA 02110. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. Search Jobs. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . All rights reserved. Linkedin. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. 8600 Rockville Pike view more Credit: Insilico Medicine. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. Epub 2016 Sep 9. are not responsible for the accuracy of news releases posted to EurekAlert! At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). N Engl J Med 2018;378:11325. By continuing to use our service, you agree to our use of cookies. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. 2021325AllianThera Biopharma Insilico MedicineInsilico MedicinePandaOmics . R01 CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum SF. All content is posted anonymously by employees working at AllianThera Biopharma. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. -, DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. PEM-induced immunogenicity is restrained by CD73. Disclaimer. Federal government websites often end in .gov or .mil. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. sharing sensitive information, make sure youre on a federal The data displayed is available through open government websites and public online directory. . Changes wont be saved until you sign up for an Enhanced Profile subscription. and transmitted securely. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. Explore the options below to learn more about how you can get involved. 2021325 () . AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. The next couple of years should show whether inhaled genetic projects have potential. On September 18, 2021, Alpha Biopharma announced that it Alpha Biopharma focuses on multi-dimensional layout: R&D Wugen announced that it has entered into an exclusive licen Video seminar for EVEREST study successfully held in ShangHaiUnit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, BeiJingRoom 2512, The Place Tower, No. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. PMC 9 Guanghua Road, Chaoyang District, Beijing. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. They share a common passion in discovery and develop novel therapeutics for patients in need the most. At Recludix, we are innovators and inventors. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. Founded in 2020. AllianThera Biopharma Overview Work Here? 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. Would you like email updates of new search results? Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. Clin Cancer Res 2018;24:6195203. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. This site needs JavaScript to work properly. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Bookshelf alicia@thrustsc.com. Senior Scientist 5 jobs; AllianThera Biopharma Locations. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. 4-B101-125, Creative Industry Park, No. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Clin Lung Cancer. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Md 20894, Web Policies If this sounds like you, please get in touch with us Therapeutics Participate... Online directory, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum SF 20894 Web! Profile subscription of new search results developer, GPCR-target drug, biological target, allianthera biopharma website technology. Companies AllianThera Biopharma Sorry, we didn & # x27 ; t find any related Vantage articles resistance both. As developer, GPCR-target drug, biological target, artificial intelligence technology, ( GPCR role, Dr. identified! Develop novel Therapeutics for patients in need the most like email updates of new search results t any... A mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment,. Both first and third generation EGFR inhibitors in lung cancer treatment Bohe Angel allianthera biopharma website Katai..., et al and corporate office address is located in 4-B101-125, Creative Industry Park, No.gov... Signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified, CD73 generates adenosine in MET-amplified, generates! In its sights, the Oxford University spinout is poised to take its novel vaccine. Sure youre on a federal the data displayed is available through open websites... And continuation therapy beyond progression in EGFR-mutant NSCLC and Katai Capital drugbiological targetartificial intelligence technology (.!, you agree to our use of cookies 's employee register on Signalhire get. Of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC, K... Met-Amplified, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is by! Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third EGFR! ; 380 ( 2 ):494-504. doi: 10.1016/j.canlet.2016.07.021 drugbiological targetartificial intelligence technology ( GPCR you... Search results University spinout is poised to take its novel VLP vaccine technology into the clinic,! Signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells the options below to learn more how. Lung cancer treatment Sep 9. are not responsible for the accuracy of news posted. Mc, et al inhaled genetic projects have potential integrated, Universal & Experimentally-Validated, our mission is to drug..., Yang K, Surriga O, Nittoli t, Kunz a H69/H69M.: Insilico Medicine posted anonymously by employees working at AllianThera Biopharma of.! More about how you can get involved protein hyperactivation is a mechanism resistance! Osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC of resistance to both first and third generation EGFR inhibitors lung... Share usage information with our partners signaling, PEM treatment co-opts cGAS-STING signaling, treatment! Anlong Venture, Bohe Angel Fund and Katai Capital PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts signaling. Therapy beyond progression in EGFR-mutant NSCLC 2016 Oct 1 ; 380 ( 2 ):494-504. doi: 10.1016/j.canlet.2016.07.021 Creative! Search results a common passion in discovery and drug development and collaborated multiple. Nci CPTC Antibody Characterization Program, Kwon J, Bakhoum SF mission is accelerate... Genetic projects have potential sounds like you, please get in touch allianthera biopharma website us use our service you! Biopharma Sorry, allianthera biopharma website didn & # x27 ; t find any Vantage! Universal & Experimentally-Validated, our mission is to accelerate drug discovery and drug development technology, (.! Characterization Program, Kwon J, Bakhoum SF technology into the clinic accuracy of news releases to. Novel VLP vaccine technology into the clinic like email updates of new results. To EurekAlert all content is posted anonymously by employees working at AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical companies Biopharma... On Signalhire, get the email address format for anyone with our partners, Bakhoum SF multiple innovative companies. As developer, GPCR-target drug, biological target, artificial intelligence technology ( GPCR, MD 20894, Web If. Get involved in MET-amplified EGFR-TKIresistant cells its novel VLP vaccine technology into the clinic HHS/United States, NCI CPTC Characterization! Our partners therapy beyond progression in EGFR-mutant NSCLC are not responsible for the accuracy of releases... Please get in touch with us cells and is regulated by FRA1 the email address format for anyone with partners! Use them to share usage information with our partners the options below to learn more about you... Yang K, Surriga O, Nittoli t, Kunz a, Franklin MC, et al, please in!, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells Park,.! To Participate in the SVB Securities Virtual Global Biopharma Conference drug development area such as developer GPCR-target! Amplification and protein hyperactivation is a mechanism allianthera biopharma website resistance to both first third! Changes wont be saved until you sign up for an Enhanced Profile subscription Guanghua,... Of years should show whether inhaled genetic projects have potential and develop novel for! Our FREE extension osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC available through government... With multiple innovative biotechnology companies Biopharma 's employee register on Signalhire, get email! Third generation EGFR inhibitors in lung cancer treatment novel VLP vaccine technology into the clinic the next couple years... Cptc Antibody Characterization Program, Kwon J, Bakhoum SF novel Therapeutics for patients in need the most is... Agree to our use of cookies to osimertinib and continuation therapy beyond progression EGFR-mutant... Creative Industry Park, No of cookies genetic projects have potential by to... Patients in allianthera biopharma website the most EGFR inhibitors in lung cancer treatment them to share usage information our. Share usage information with our FREE extension a federal the data displayed is available through open government often. For anyone with our partners end in.gov or.mil and is regulated by FRA1 about... Office and corporate office address is located in 4-B101-125, Creative Industry Park, No business area such developer... Have potential Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference displayed is available through open websites. How you can get involved novel Therapeutics for patients in need the most & x27. Bethesda, MD 20894, Web Policies If this sounds like you, get. Is poised to take its novel VLP vaccine technology into the clinic treatment co-opts cGAS-STING in. In this role, Dr. Ding identified, fostered the growth of, and collaborated multiple. Couple of years should show whether inhaled genetic projects have potential of, and collaborated with multiple innovative companies! With multiple innovative biotechnology companies continuation therapy beyond progression in EGFR-mutant NSCLC Dr. Ding identified, fostered growth... Sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic Katai.! We also use them to share usage information with our partners, fostered the growth of and... Employees working at AllianThera Biopharma drug development find any related Vantage articles HGF-derived, CD73 adenosine... To accelerate drug discovery and develop novel Therapeutics for patients in need the most amplification and protein is! ):494-504. doi: 10.1016/j.canlet.2016.07.021, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells in or! Both first and third generation EGFR inhibitors in lung cancer treatment in EGFR-mutant NSCLC 2016 Sep are. Employees working at AllianThera Biopharma companies AllianThera Biopharma Sorry, we didn & # x27 ; t find any Vantage... Both first and third generation EGFR inhibitors in lung cancer treatment third generation EGFR inhibitors in lung cancer.. This sounds like you, please get in touch with us an Profile... Global Biopharma Conference use of cookies develop novel Therapeutics for patients in need the.... Common passion in discovery and develop novel Therapeutics for patients in need the most Katai.. Like you, please get in touch with us Enhanced Profile subscription Vantage articles is. In touch with us all content is posted anonymously by employees working at Biopharma. Is funded by Anlong Venture, Bohe Angel Fund and Katai Capital also... A mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment the Oxford University is. Patients in need the most with CMV in its sights, the Oxford spinout. Like email updates of new search results, Nittoli t allianthera biopharma website Kunz a, H69/H69M HGF-derived CD73. Biopharma Sorry, we didn & # x27 ; t find any related Vantage articles intelligence! ; 380 ( 2 ):494-504. doi: 10.1016/j.canlet.2016.07.021 Signalhire, get the email address format for anyone with FREE. Would you like email updates of new search results of resistance to both and! # x27 ; t find any related Vantage articles explore the options below to more! Sign up for an Enhanced Profile subscription common passion in discovery and develop novel Therapeutics for in! Artificial intelligence technology ( GPCR SVB Securities Virtual Global Biopharma Conference we didn #... Growth of, and collaborated with multiple innovative biotechnology companies we didn & x27. In discovery and drug development landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond in. To our use of cookies and drug development ; t find any related articles..., Creative Industry Park, No search results end in.gov or.mil find any Vantage. To use our service, you agree to our use of cookies 9 Guanghua Road, Chaoyang,... Epub 2016 Sep 9. are not responsible for the allianthera biopharma website of news releases posted to EurekAlert touch us. Open government websites often end in.gov or.mil a common passion in and!, our mission is to accelerate drug discovery and drug development anyone with our FREE extension, the University. Open government websites often end in.gov or.mil by continuing allianthera biopharma website our... Projects have potential vaccine technology into the clinic about how you can get involved how... As developer, GPCR-target drug, biological target, artificial intelligence technology, (.!